Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy

Genomic alterations in circulating tumor DNA (ctDNA) are associated with clinical outcomes in treatment-naive metastatic castration-resistant prostate cancer (mCRPC) patients commencing androgen receptor (AR)-targeted therapy

Saved in:
Bibliographic Details
Published in:Annals of oncology Vol. 27; p. vi17
Main Authors: Wyatt, A.W., Annala, M., Beja, K., Parimi, S., Vandekerkhove, G., Warner, E., Zulfiqar, M., Finch, D., Oja, C., Vergidis, J., Nykter, M., Gleave, M.E., Chi, K.
Format: Journal Article
Language:English
Published: Elsevier Ltd 01-10-2016
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:0923-7534
1569-8041
DOI:10.1093/annonc/mdw363.08